Report cover image

Global NK-1 Receptor Antagonists Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 08, 2025
Length 209 Pages
SKU # APRC20279834

Description

Summary

According to APO Research, the global NK-1 Receptor Antagonists market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the NK-1 Receptor Antagonists market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for NK-1 Receptor Antagonists is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the NK-1 Receptor Antagonists market include Dr. Reddy's Laboratories, Eugia Pharma, Fresenius Kabi, Glenmark, Helsinn Healthcare, Heron Therapeutics, Lupin, MSN and Mylan, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for NK-1 Receptor Antagonists, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of NK-1 Receptor Antagonists, also provides the sales of main regions and countries. Of the upcoming market potential for NK-1 Receptor Antagonists, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the NK-1 Receptor Antagonists sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global NK-1 Receptor Antagonists market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for NK-1 Receptor Antagonists sales, projected growth trends, production technology, application and end-user industry.

NK-1 Receptor Antagonists Segment by Company

Dr. Reddy's Laboratories
Eugia Pharma
Fresenius Kabi
Glenmark
Helsinn Healthcare
Heron Therapeutics
Lupin
MSN
Mylan
Steriscience
TerSera Therapeutics
Teva
Torrent Pharmaceuticals
Beijing Sihuan Pharmaceutical
Hansoh Pharma
Merck
Qilu Pharmaceutical
Sandoz
Yichang Humanwell Pharmaceutical
Chia Tai Tianqing Pharmaceutical
NK-1 Receptor Antagonists Segment by Type

Netupitant
Maropitant
Rolapitant
Fosaprepitant
Aprepitant
Other
NK-1 Receptor Antagonists Segment by Application

Chemotherapy-induced Nausea and Vomiting (CINV)
Postoperative Nausea and Vomiting (PONV)
Other
NK-1 Receptor Antagonists Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global NK-1 Receptor Antagonists status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions NK-1 Receptor Antagonists market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify NK-1 Receptor Antagonists significant trends, drivers, influence factors in global and regions.
6. To analyze NK-1 Receptor Antagonists competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK-1 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of NK-1 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK-1 Receptor Antagonists.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NK-1 Receptor Antagonists market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NK-1 Receptor Antagonists industry.
Chapter 3: Detailed analysis of NK-1 Receptor Antagonists manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of NK-1 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of NK-1 Receptor Antagonists in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

209 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global NK-1 Receptor Antagonists Sales Value (2020-2031)
1.2.2 Global NK-1 Receptor Antagonists Sales Volume (2020-2031)
1.2.3 Global NK-1 Receptor Antagonists Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 NK-1 Receptor Antagonists Market Dynamics
2.1 NK-1 Receptor Antagonists Industry Trends
2.2 NK-1 Receptor Antagonists Industry Drivers
2.3 NK-1 Receptor Antagonists Industry Opportunities and Challenges
2.4 NK-1 Receptor Antagonists Industry Restraints
3 NK-1 Receptor Antagonists Market by Company
3.1 Global NK-1 Receptor Antagonists Company Revenue Ranking in 2024
3.2 Global NK-1 Receptor Antagonists Revenue by Company (2020-2025)
3.3 Global NK-1 Receptor Antagonists Sales Volume by Company (2020-2025)
3.4 Global NK-1 Receptor Antagonists Average Price by Company (2020-2025)
3.5 Global NK-1 Receptor Antagonists Company Ranking (2023-2025)
3.6 Global NK-1 Receptor Antagonists Company Manufacturing Base and Headquarters
3.7 Global NK-1 Receptor Antagonists Company Product Type and Application
3.8 Global NK-1 Receptor Antagonists Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global NK-1 Receptor Antagonists Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 NK-1 Receptor Antagonists Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 NK-1 Receptor Antagonists Market by Type
4.1 NK-1 Receptor Antagonists Type Introduction
4.1.1 Netupitant
4.1.2 Maropitant
4.1.3 Rolapitant
4.1.4 Fosaprepitant
4.1.5 Aprepitant
4.1.6 Other
4.2 Global NK-1 Receptor Antagonists Sales Volume by Type
4.2.1 Global NK-1 Receptor Antagonists Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global NK-1 Receptor Antagonists Sales Volume by Type (2020-2031)
4.2.3 Global NK-1 Receptor Antagonists Sales Volume Share by Type (2020-2031)
4.3 Global NK-1 Receptor Antagonists Sales Value by Type
4.3.1 Global NK-1 Receptor Antagonists Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global NK-1 Receptor Antagonists Sales Value by Type (2020-2031)
4.3.3 Global NK-1 Receptor Antagonists Sales Value Share by Type (2020-2031)
5 NK-1 Receptor Antagonists Market by Application
5.1 NK-1 Receptor Antagonists Application Introduction
5.1.1 Chemotherapy-induced Nausea and Vomiting (CINV)
5.1.2 Postoperative Nausea and Vomiting (PONV)
5.1.3 Other
5.2 Global NK-1 Receptor Antagonists Sales Volume by Application
5.2.1 Global NK-1 Receptor Antagonists Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global NK-1 Receptor Antagonists Sales Volume by Application (2020-2031)
5.2.3 Global NK-1 Receptor Antagonists Sales Volume Share by Application (2020-2031)
5.3 Global NK-1 Receptor Antagonists Sales Value by Application
5.3.1 Global NK-1 Receptor Antagonists Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global NK-1 Receptor Antagonists Sales Value by Application (2020-2031)
5.3.3 Global NK-1 Receptor Antagonists Sales Value Share by Application (2020-2031)
6 NK-1 Receptor Antagonists Regional Sales and Value Analysis
6.1 Global NK-1 Receptor Antagonists Sales by Region: 2020 VS 2024 VS 2031
6.2 Global NK-1 Receptor Antagonists Sales by Region (2020-2031)
6.2.1 Global NK-1 Receptor Antagonists Sales by Region: 2020-2025
6.2.2 Global NK-1 Receptor Antagonists Sales by Region (2026-2031)
6.3 Global NK-1 Receptor Antagonists Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global NK-1 Receptor Antagonists Sales Value by Region (2020-2031)
6.4.1 Global NK-1 Receptor Antagonists Sales Value by Region: 2020-2025
6.4.2 Global NK-1 Receptor Antagonists Sales Value by Region (2026-2031)
6.5 Global NK-1 Receptor Antagonists Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America NK-1 Receptor Antagonists Sales Value (2020-2031)
6.6.2 North America NK-1 Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe NK-1 Receptor Antagonists Sales Value (2020-2031)
6.7.2 Europe NK-1 Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific NK-1 Receptor Antagonists Sales Value (2020-2031)
6.8.2 Asia-Pacific NK-1 Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America NK-1 Receptor Antagonists Sales Value (2020-2031)
6.9.2 South America NK-1 Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa NK-1 Receptor Antagonists Sales Value (2020-2031)
6.10.2 Middle East & Africa NK-1 Receptor Antagonists Sales Value Share by Country, 2024 VS 2031
7 NK-1 Receptor Antagonists Country-level Sales and Value Analysis
7.1 Global NK-1 Receptor Antagonists Sales by Country: 2020 VS 2024 VS 2031
7.2 Global NK-1 Receptor Antagonists Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global NK-1 Receptor Antagonists Sales by Country (2020-2031)
7.3.1 Global NK-1 Receptor Antagonists Sales by Country (2020-2025)
7.3.2 Global NK-1 Receptor Antagonists Sales by Country (2026-2031)
7.4 Global NK-1 Receptor Antagonists Sales Value by Country (2020-2031)
7.4.1 Global NK-1 Receptor Antagonists Sales Value by Country (2020-2025)
7.4.2 Global NK-1 Receptor Antagonists Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.5.2 USA NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.5.3 USA NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.6.2 Canada NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.6.2 Mexico NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.8.2 Germany NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.9.2 France NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.9.3 France NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.10.2 U.K. NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.11.2 Italy NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.12.2 Spain NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.13.2 Russia NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.16.2 China NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.16.3 China NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.17.2 Japan NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.18.2 South Korea NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.19.2 India NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.19.3 India NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.20.2 Australia NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.22.2 Brazil NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.23.2 Argentina NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.24.2 Chile NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.25.2 Colombia NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.26.2 Peru NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.28.2 Israel NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.29.2 UAE NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.30.2 Turkey NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.31.2 Iran NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt NK-1 Receptor Antagonists Sales Value Growth Rate (2020-2031)
7.32.2 Egypt NK-1 Receptor Antagonists Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt NK-1 Receptor Antagonists Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Dr. Reddy's Laboratories
8.1.1 Dr. Reddy's Laboratories Comapny Information
8.1.2 Dr. Reddy's Laboratories Business Overview
8.1.3 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.1.4 Dr. Reddy's Laboratories NK-1 Receptor Antagonists Product Portfolio
8.1.5 Dr. Reddy's Laboratories Recent Developments
8.2 Eugia Pharma
8.2.1 Eugia Pharma Comapny Information
8.2.2 Eugia Pharma Business Overview
8.2.3 Eugia Pharma NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.2.4 Eugia Pharma NK-1 Receptor Antagonists Product Portfolio
8.2.5 Eugia Pharma Recent Developments
8.3 Fresenius Kabi
8.3.1 Fresenius Kabi Comapny Information
8.3.2 Fresenius Kabi Business Overview
8.3.3 Fresenius Kabi NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.3.4 Fresenius Kabi NK-1 Receptor Antagonists Product Portfolio
8.3.5 Fresenius Kabi Recent Developments
8.4 Glenmark
8.4.1 Glenmark Comapny Information
8.4.2 Glenmark Business Overview
8.4.3 Glenmark NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.4.4 Glenmark NK-1 Receptor Antagonists Product Portfolio
8.4.5 Glenmark Recent Developments
8.5 Helsinn Healthcare
8.5.1 Helsinn Healthcare Comapny Information
8.5.2 Helsinn Healthcare Business Overview
8.5.3 Helsinn Healthcare NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.5.4 Helsinn Healthcare NK-1 Receptor Antagonists Product Portfolio
8.5.5 Helsinn Healthcare Recent Developments
8.6 Heron Therapeutics
8.6.1 Heron Therapeutics Comapny Information
8.6.2 Heron Therapeutics Business Overview
8.6.3 Heron Therapeutics NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.6.4 Heron Therapeutics NK-1 Receptor Antagonists Product Portfolio
8.6.5 Heron Therapeutics Recent Developments
8.7 Lupin
8.7.1 Lupin Comapny Information
8.7.2 Lupin Business Overview
8.7.3 Lupin NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.7.4 Lupin NK-1 Receptor Antagonists Product Portfolio
8.7.5 Lupin Recent Developments
8.8 MSN
8.8.1 MSN Comapny Information
8.8.2 MSN Business Overview
8.8.3 MSN NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.8.4 MSN NK-1 Receptor Antagonists Product Portfolio
8.8.5 MSN Recent Developments
8.9 Mylan
8.9.1 Mylan Comapny Information
8.9.2 Mylan Business Overview
8.9.3 Mylan NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.9.4 Mylan NK-1 Receptor Antagonists Product Portfolio
8.9.5 Mylan Recent Developments
8.10 Steriscience
8.10.1 Steriscience Comapny Information
8.10.2 Steriscience Business Overview
8.10.3 Steriscience NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.10.4 Steriscience NK-1 Receptor Antagonists Product Portfolio
8.10.5 Steriscience Recent Developments
8.11 TerSera Therapeutics
8.11.1 TerSera Therapeutics Comapny Information
8.11.2 TerSera Therapeutics Business Overview
8.11.3 TerSera Therapeutics NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.11.4 TerSera Therapeutics NK-1 Receptor Antagonists Product Portfolio
8.11.5 TerSera Therapeutics Recent Developments
8.12 Teva
8.12.1 Teva Comapny Information
8.12.2 Teva Business Overview
8.12.3 Teva NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.12.4 Teva NK-1 Receptor Antagonists Product Portfolio
8.12.5 Teva Recent Developments
8.13 Torrent Pharmaceuticals
8.13.1 Torrent Pharmaceuticals Comapny Information
8.13.2 Torrent Pharmaceuticals Business Overview
8.13.3 Torrent Pharmaceuticals NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.13.4 Torrent Pharmaceuticals NK-1 Receptor Antagonists Product Portfolio
8.13.5 Torrent Pharmaceuticals Recent Developments
8.14 Beijing Sihuan Pharmaceutical
8.14.1 Beijing Sihuan Pharmaceutical Comapny Information
8.14.2 Beijing Sihuan Pharmaceutical Business Overview
8.14.3 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.14.4 Beijing Sihuan Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
8.14.5 Beijing Sihuan Pharmaceutical Recent Developments
8.15 Hansoh Pharma
8.15.1 Hansoh Pharma Comapny Information
8.15.2 Hansoh Pharma Business Overview
8.15.3 Hansoh Pharma NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.15.4 Hansoh Pharma NK-1 Receptor Antagonists Product Portfolio
8.15.5 Hansoh Pharma Recent Developments
8.16 Merck
8.16.1 Merck Comapny Information
8.16.2 Merck Business Overview
8.16.3 Merck NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.16.4 Merck NK-1 Receptor Antagonists Product Portfolio
8.16.5 Merck Recent Developments
8.17 Qilu Pharmaceutical
8.17.1 Qilu Pharmaceutical Comapny Information
8.17.2 Qilu Pharmaceutical Business Overview
8.17.3 Qilu Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.17.4 Qilu Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
8.17.5 Qilu Pharmaceutical Recent Developments
8.18 Sandoz
8.18.1 Sandoz Comapny Information
8.18.2 Sandoz Business Overview
8.18.3 Sandoz NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.18.4 Sandoz NK-1 Receptor Antagonists Product Portfolio
8.18.5 Sandoz Recent Developments
8.19 Yichang Humanwell Pharmaceutical
8.19.1 Yichang Humanwell Pharmaceutical Comapny Information
8.19.2 Yichang Humanwell Pharmaceutical Business Overview
8.19.3 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.19.4 Yichang Humanwell Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
8.19.5 Yichang Humanwell Pharmaceutical Recent Developments
8.20 Chia Tai Tianqing Pharmaceutical
8.20.1 Chia Tai Tianqing Pharmaceutical Comapny Information
8.20.2 Chia Tai Tianqing Pharmaceutical Business Overview
8.20.3 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Sales, Value and Gross Margin (2020-2025)
8.20.4 Chia Tai Tianqing Pharmaceutical NK-1 Receptor Antagonists Product Portfolio
8.20.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 NK-1 Receptor Antagonists Value Chain Analysis
9.1.1 NK-1 Receptor Antagonists Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 NK-1 Receptor Antagonists Sales Mode & Process
9.2 NK-1 Receptor Antagonists Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 NK-1 Receptor Antagonists Distributors
9.2.3 NK-1 Receptor Antagonists Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.